Martin Vogel

Summary

Affiliation: University of Bonn
Country: Germany

Publications

  1. ncbi Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases
    M Vogel
    Medizinische Klinik und Poliklinik I, Bonn University, Germany
    J Viral Hepat 12:207-11. 2005
  2. ncbi The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals
    M Vogel
    Department of Internal Medicine I, Rheinische Friedrich Wilhelms University, Germany
    Eur J Med Res 15:102-11. 2010
  3. ncbi Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence
    M Vogel
    Department of Internal Medicine I, Bonn University, Sigmund Freud Str 25, 53105 Bonn, Germany
    Eur J Med Res 16:101-7. 2011
  4. ncbi [Therapy of hepatitis B and hepatitis C coinfection in HIV patients]
    M Vogel
    Medizinische Universitatsklinik I, Bonn
    MMW Fortschr Med 147:56-9. 2005
  5. ncbi Highlights of the third international workshop on HIV and hepatitis coinfection
    Martin Vogel
    University Hospital Bonn, Department of Internal Medicine I, 53105 Bonn, Germany
    Expert Rev Anti Infect Ther 5:769-71. 2007
  6. ncbi Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany
    Martin Vogel
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Liver Int 30:1169-72. 2010
  7. ncbi Acute hepatitis C infection in HIV-positive patients
    Martin Vogel
    Department of Internal Medicine III, Bonn University, Bonn, Germany
    Curr Opin Infect Dis 24:1-6. 2011
  8. ncbi Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort
    Martin Vogel
    Department of Internal Medicine I, Bonn University, Bonn, Germany
    Antivir Ther 15:267-79. 2010
  9. ncbi The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C
    Jacob Nattermann
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    AIDS 22:1287-92. 2008
  10. ncbi Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients
    Jacob Nattermann
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Hepatology 46:1016-25. 2007

Detail Information

Publications42

  1. ncbi Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases
    M Vogel
    Medizinische Klinik und Poliklinik I, Bonn University, Germany
    J Viral Hepat 12:207-11. 2005
    ..In conclusion, early treatment of acute hepatitis C seems to achieve high sustained virological treatment response rates also in patients with HIV-infection...
  2. ncbi The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals
    M Vogel
    Department of Internal Medicine I, Rheinische Friedrich Wilhelms University, Germany
    Eur J Med Res 15:102-11. 2010
    ..In addition a control group of HCV mono-infected patients undergoing anti-HCV therapy was evaluated...
  3. ncbi Cancer risk in HIV-infected individuals on HAART is largely attributed to oncogenic infections and state of immunocompetence
    M Vogel
    Department of Internal Medicine I, Bonn University, Sigmund Freud Str 25, 53105 Bonn, Germany
    Eur J Med Res 16:101-7. 2011
    ..To estimate the cancer risk of HIV-infected patients in the HAART era with respect to a general reference population and to determine risk factors for malignancy...
  4. ncbi [Therapy of hepatitis B and hepatitis C coinfection in HIV patients]
    M Vogel
    Medizinische Universitatsklinik I, Bonn
    MMW Fortschr Med 147:56-9. 2005
    ..Thus, HAART should not be withheld from a patient because of hepatitis coinfection. When cirrhosis is present, semiannual prophylactic checkups are recommended to monitor the occurrence of hepatocellular carcinoma...
  5. ncbi Highlights of the third international workshop on HIV and hepatitis coinfection
    Martin Vogel
    University Hospital Bonn, Department of Internal Medicine I, 53105 Bonn, Germany
    Expert Rev Anti Infect Ther 5:769-71. 2007
  6. ncbi Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany
    Martin Vogel
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Liver Int 30:1169-72. 2010
    ..Recently in the North-Rhine region of Germany, we have observed an increase in acute HCV infections of genotype 4 (HCV-4)...
  7. ncbi Acute hepatitis C infection in HIV-positive patients
    Martin Vogel
    Department of Internal Medicine III, Bonn University, Bonn, Germany
    Curr Opin Infect Dis 24:1-6. 2011
    ....
  8. ncbi Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort
    Martin Vogel
    Department of Internal Medicine I, Bonn University, Bonn, Germany
    Antivir Ther 15:267-79. 2010
    ..Early treatment of acute HCV infection has been shown to improve virological response rates in HIV-positive patients; however, details on when and how to best treat acute HCV infection remain unclear at present...
  9. ncbi The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C
    Jacob Nattermann
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    AIDS 22:1287-92. 2008
    ..Here, we studied whether transforming growth factor-beta gene polymorphisms affect treatment response in HCV/HIV coinfection...
  10. ncbi Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients
    Jacob Nattermann
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Hepatology 46:1016-25. 2007
    ..CONCLUSION: Response rates to HCV-specific treatment are higher in HCV/HIV-positive patients carrying the IL-6 HP genotype, which might be because of IL-6 mediated STAT3 activation...
  11. ncbi The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection
    Hans Dieter Nischalke
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    AIDS 24:2001-7. 2010
    ..Here, we analyzed the potential impact of the CTLA4 polymorphisms on response to hepatitis C virus (HCV)-specific treatment in HIV(+) patients co-infected with HCV...
  12. ncbi Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C
    Jacob Nattermann
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    J Infect Dis 203:595-601. 2011
    ..Thus, effects of the IL28B single-nucleotide polymorphism may differ in HIV-infected patients with chronic and acute hepatitis C...
  13. ncbi Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals
    Martin Vogel
    Department of Internal Medicine I, Bonn University, Germany
    Clin Infect Dis 54:556-9. 2012
    ..The duration of follow-up and serum alanine transaminase correlated with liver stiffness, and short follow-up resulted in high fibrosis progression rates...
  14. ncbi The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients
    Golo Ahlenstiel
    Department of Internal Medicine I, University of Bonn, Sigmund Freud Street 25, 53105 Bonn, Germany
    J Hepatol 47:348-55. 2007
    ..The G protein beta3 unit (GNB3) C825T polymorphism has been shown to affect treatment response in HCV mono-infection. Here, we analyzed the impact of the GNB3 genotype in the context of HCV/HIV co-infection...
  15. ncbi HIV and hepatitis C co-infection: acute HCV therapy
    Christoph Boesecke
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Curr Opin HIV AIDS 6:459-64. 2011
    ..However, to give clinicians guidance in best clinical management of these patients expert consensus recommendations based upon published data from uncontrolled clinical and cohort studies have recently been published...
  16. ncbi The HLA-E(R)/HLA-E(R) genotype affects the natural course of hepatitis C virus (HCV) infection and is associated with HLA-E-restricted recognition of an HCV-derived peptide by interferon-gamma-secreting human CD8(+) T cells
    Daniela Schulte
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    J Infect Dis 200:1397-401. 2009
    ..038). Moreover, we found that the HLA-E(R) allelic variant confers protection against chronic infection with HCV genotypes 2 and 3. Taken together, our data indicate an important immunomodulating function of HLA-E in hepatitis C...
  17. ncbi Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level
    Golo Ahlenstiel
    Department of Internal Medicine I, University of Bonn, 53105 Bonn, Germany
    Clin Vaccine Immunol 14:1266-73. 2007
    ..As several of the HLA-associated mutations lie at positions associated with drug resistance, our results indicate possible negative effects of HLA genotypes on the development of HIV-1 drug resistance...
  18. ncbi Hepatitis C-associated autoimmunity in patients coinfected with HIV
    Rainer P Woitas
    Department of Internal Medicine I, University of Bonn, 53105 Bonn, Germany
    Liver Int 25:1114-21. 2005
    ..Hepatitis C virus (HCV) infection is associated with multiple extrahepatic manifestations. It is unclear to what extent extrahepatic manifestations occur in HIV/HCV coinfection...
  19. ncbi Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals
    Martin Vogel
    Department of Medicine I, University of Bonn, Germany
    Antivir Ther 11:1097-101. 2006
    ..CONCLUSIONS: Treatment of hepatitis C in HIV-positive individuals in the acute phase of infection leads to high rates of sustained virological response. Optimal time and mode of therapy have yet to be defined...
  20. ncbi Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients
    Mathias Lichterfeld
    Department of General Internal Medicine, Rheinische Friedrich Wilhelms Universitat, 53105 Bonn, Germany
    J Infect 50:221-8. 2005
    ..To determine the disease progression of HIV-HCV co-infected hemophiliacs in a large cohort of patients (n = 288) cared for at a single medical institution...
  21. ncbi Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation
    Martin Vogel
    Department of Internal Medicine I, Bonn University, Bonn, Germany
    Curr Opin HIV AIDS 4:171-5. 2009
    ..In the following review, we discuss current data on the effects of HAART in the context of concurrent hepatitis B and C infection...
  22. ncbi Treatment of acute hepatitis C in HIV infection
    Martin Vogel
    Department of Internal Medicine I, Bonn University, Germany
    J Antimicrob Chemother 65:4-9. 2010
    ..Though data are sparse, controlling treatment response at weeks 4 and 12 may further help to individualize therapy, and patients who have not reached a negative HCV RNA by week 12 may benefit from prolonged treatment beyond 24 weeks...
  23. ncbi The treatment of chronic hepatitis C virus infection in HIV co-infection
    Martin Vogel
    Department of Internal Medicine I, Bonn University, Bonn, Germany
    Eur J Med Res 14:507-15. 2009
    ..However, these substances will probably reach clinical routine for HIV patients later than HCV monoinfected patients. Therefore at present waiting for new drugs is not an alternative to a modern pegylated interferon/ribavirin therapy...
  24. ncbi Safety of lopinavir/ritonavir for the treatment of HIV-infection
    Martin Vogel
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Expert Opin Drug Saf 4:403-20. 2005
    ..In this review, the authors report on the safety of lopinavir/ritonavir in the treatment of HIV-infected patients, and focus on special patient groups and relevant safety issues...
  25. ncbi Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals
    Martin Vogel
    Department of Internal Medicine I, Bonn University, Germany
    J Antimicrob Chemother 63:988-91. 2009
    ..This study was undertaken to assess the differences in the pharmacokinetics of nevirapine between patients with HIV/HCV coinfection and HIV infection that could explain higher rates of hepatotoxicity...
  26. ncbi Therapy of hepatitis C in HIV-coinfection
    J K Rockstroh
    Medizinische Universitatsklinik I, Sigmund Freud Strasse 25, D 53105 Bonn, Germany
    Eur J Med Res 9:304-8. 2004
    ....
  27. ncbi Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results
    E Voigt
    Department of Internal Medicine, University of Bonn, Sigmund Freud Str 25, D 53105, Bonn, Germany
    Infection 32:82-8. 2004
    ..Within this open-label, uncontrolled prospective trial we evaluated safety, efficacy and development of genotypic resistance under the new protease inhibitor lopinavir/ritonavir (LPV/r) in antiretroviral (ARV) HIV patients...
  28. ncbi Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity
    J C Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105, Bonn, Germany
    Eur J Clin Pharmacol 63:901-8. 2007
    ..We tested whether dose reduction of IDV guided by therapeutic drug monitoring resulted in improved tolerability without compromising antiviral efficacy...
  29. ncbi Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring
    J C Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
    Eur J Med Res 12:289-94. 2007
    ..To compare two reduced dose indinavir (IDV) + ritonavir (RTV) combinations guided by therapeutic drug monitoring (TDM) in treatment-naive HIV1-infected patients...
  30. ncbi Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment
    Oliver Schildgen
    , , 53105 Bonn, Germany
    AIDS 18:2325-7. 2004
    ..In all cases adefovir was replaced by tenofovir, resulting in a significant drop in the viral load...
  31. ncbi Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort
    Martin Vogel
    Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany
    Liver Transpl 11:1515-21. 2005
    ..In conclusion, even though preliminary, our data suggest that outcomes after liver transplantation of HIV-infected patients can be improved...
  32. ncbi Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control
    S C Blass
    Department of Nutrition and Food Sciences, Nutritional Physiology, University Hospital of Bonn, Bonn, Germany
    Eur J Med Res 13:209-14. 2008
    ..The aim of our study was to identify patients at high risk for abnormalities in glucose metabolism taking into account HAART, familial disposition for DM and anthropometric parameters...
  33. ncbi Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiation
    P Ingiliz
    Department of Medicine I, University of Bonn, Bonn, Germany
    HIV Med 7:411-4. 2006
    ..He improved dramatically after treatment with oral steroids...
  34. ncbi Hepatotoxicity and liver disease in the context of HIV therapy
    Martin Vogel
    Department of Medicine I, University of Bonn, Bonn, Germany
    Curr Opin HIV AIDS 2:306-13. 2007
    ..Hypersensitivity reactions may take a rapid and fulminant course, and thorough information for the patient is vital in the early detection of symptoms and prevention of life-threatening complications...
  35. ncbi Determination of nevirapine in plasma by GC-MS
    M Vogel
    Department of Internal Medicine I, Bonn University, Bonn, Germany
    J Chromatogr Sci 48:91-4. 2010
    ..GC-MS proved to be a valid alternative to high-performance liquid chromatography and liquid chromatography-MS...
  36. ncbi Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Boston, Massachusetts, USA
    AIDS 17:2581-91. 2003
    ..CONCLUSION: These data demonstrate that host genetic factors can influence the clinical manifestations of acute HIV-1 infection and provide a functional link between HLA-B57 and viral immune control...
  37. ncbi Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study
    Luz Martin-Carbonero
    Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 38:128-33. 2004
    ..The rate of complications due to end-stage liver disease will inevitably increase in this population, for whom anti-HCV therapy should be considered a priority...
  38. ncbi Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort
    Kamila Wojcik
    Department of Infectious Diseases and Hepatology, Medical University of Lodz, 91 347 Lodz, Poland
    AIDS 21:1363-5. 2007
    ..At experienced centres interferon treatment is a valuable option for recurrent hepatitis C in HIV-positive patients...
  39. ncbi Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients
    Martin Vogel
    Department of Internal Medicine I, University of Bonn, Germany
    Liver Transpl 10:939-44. 2004
    ..Because of the flat absorption/elimination profiles under ritonavir-boosted HAART cyclosporine A, dosing could be reliably monitored long term by measuring cyclosporine A trough-levels...
  40. ncbi Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients
    Manon van der Lee
    Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Antivir Ther 12:1127-32. 2007
    ..This study explored the lipid-lowering effect of rosuvastatin and assessed the effect of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin and vice versa...
  41. ncbi Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
    Christoph Wyen
    Department of Internal Medicine, University of Cologne, Koln, Germany
    J Antimicrob Chemother 61:914-8. 2008
    ..The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the influence of heterozygosity and homozygosity on plasma concentrations of efavirenz and nevirapine...
  42. ncbi Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men
    Alexander Kreuter
    1Department of Dermatology, Ruhr University Bochum, Bochum, Germany
    J Invest Dermatol 128:2078-83. 2008
    ..However, new AIN lesions associated with previously undetected HPV types frequently occur in untreated areas...